Format

Send to

Choose Destination
Cardiovasc Diabetol. 2017 Jan 13;16(1):9. doi: 10.1186/s12933-016-0489-z.

Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes.

Author information

1
Department of Medicine, Division of Endocrinology, Diabetes and Cardiovascular Center, University of Missouri, School of Medicine, Columbia, USA.
2
Research Service, Harry S. Truman Memorial Veterans Hospital, Columbia, MO, USA.
3
Department of Medical Pharmacology and Physiology, University of Missouri, School of Medicine, Columbia, USA.
4
The Dalton Cardiovascular Research Center, Columbia, MO, USA.
5
Department of Cardiometabolic Diseases Research, Boehringer-Ingelheim, Biberach, Germany.
6
Departments of Medicine-Gastroenterology and Hepatology and Nutrition and Exercise Physiology, University of Missouri, Columbia, MO, USA.
7
Division of Nephrology, University of Missouri, School of Medicine, Columbia, USA.
8
Department of Medicine, Division of Endocrinology, Diabetes and Cardiovascular Center, University of Missouri, School of Medicine, Columbia, USA. demarcov@missouri.edu.
9
Department of Medical Pharmacology and Physiology, University of Missouri, School of Medicine, Columbia, USA. demarcov@missouri.edu.
10
Research Service, Harry S. Truman Memorial Veterans Hospital, Columbia, MO, USA. demarcov@missouri.edu.

Abstract

Obese and diabetic individuals are at increased risk for impairments in diastolic relaxation and heart failure with preserved ejection fraction. The impairments in diastolic relaxation are especially pronounced in obese and diabetic women and predict future cardiovascular disease (CVD) events in this population. Recent clinical data suggest sodium glucose transporter-2 (SGLT2) inhibition reduces CVD events in diabetic individuals, but the mechanisms of this CVD protection are unknown. To determine whether targeting SGLT2 improves diastolic relaxation, we utilized empagliflozin (EMPA) in female db/db mice. Eleven week old female db/db mice were fed normal mouse chow, with or without EMPA, for 5 weeks. Blood pressure (BP), HbA1c and fasting glucose were significantly increased in untreated db/db mice (DbC) (P < 0.01). EMPA treatment (DbE) improved glycemic indices (P < 0.05), but not BP (P > 0.05). At baseline, DbC and DbE had already established impaired diastolic relaxation as indicated by impaired septal wall motion (>tissue Doppler derived E'/A' ratio) and increased left ventricular (LV) filling pressure (<E/E' ratio). Although these abnormalities persisted throughout the study period in DbC, diastolic function improved with EMPA treatment. In DbC, myocardial fibrosis was accompanied by increased expression of profibrotic/prohypertrophic proteins, serum/glucocorticoid regulated kinase 1 (SGK1) and the epithelial sodium channel (ENaC), and the development of these abnormalities were reduced with EMPA. DbC exhibited eccentric LV hypertrophy that was slightly improved by EMPA, indicated by a reduction in cardiomyocyte cross sectional area. In summary, EMPA improved glycemic indices along with diastolic relaxation, as well as SGK1/ENaC profibrosis signaling and associated interstitial fibrosis, all of which occurred in the absence of any changes in BP.

KEYWORDS:

Diastolic function; Empagliflozin; SGLT2 inhibitor

PMID:
28086951
PMCID:
PMC5237274
DOI:
10.1186/s12933-016-0489-z
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center